582.46
+3.64%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About United Therapeutics
From its filings with the US Securities and Exchange Commission
United Therapeutics is based in Silver Spring, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker UTHR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $3.18bn and net income of $1.33bn. At that date it held total assets of $7.88bn and shareholders' equity of $7.10bn.
Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.
As a public benefit corporation (PBC), we aim to deliver meaningful impacts for our patients, our people, our shareholders, and other stakeholders. Our public benefit purpose, as outlined in our charter and approved by our shareholders, is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
Tyvaso DPI and Nebulized Tyvaso are also approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).
In the United States, we also market and sell an oncology product, Unituxin® (dinutuximab) Injection (Unituxin), which is approved by the FDA for the treatment of high-risk neuroblastoma. Outside the United States, we derive revenues from sales of Nebulized Tyvaso, Remodulin, and Unituxin.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jun 1999
- Employees
- 1,400
- Website
- unither.com ↗
- Head office
- 1000 SPRING ST, SILVER SPRING, MD, 20910
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Martine RothblattChairman of the Board, Chief Executive Officer, since 1996$23.0m
- Mr. Michael BenkowitzPresident, Chief Operating Officer$13.9m
- Mr. Christopher PatuskyLead Independent Vice Chairman of the Board$514,567
- Mr. James EdgemondChief Financial Officer, Treasurer$9.2m
- Mr. Paul MahonExecutive Vice President, General Counsel, Corporate Secretary$7.0m
- Ms. Jan MalcolmDirector$795,174
- Mr. Christopher CauseyIndependent Director$500,280
- Prof. Raymond DwekIndependent Director$438,475
- Mr. Richard GiltnerIndependent Director$500,280
- Mr. Raymond KurzweilIndependent Director$439,567
- Dr. Linda MaxwellIndependent Director$438,475
- Prof. Nilda MesaIndependent Director$469,567
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 71
- Environment
- 41
- Social
- 90
- Governance
- 80
- Women in the workforce
- 52%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Presence: United Therapeutics Corp has gained a strong footing in the pharmaceutical industry through its years of operation.
- Diverse Product Portfolio: The company offers a wide range of medications and therapies, catering to various medical conditions and patient needs.
- Robust Research and Development: United Therapeutics Corp maintains a strong focus on innovation and continually invests in R&D to develop new treatments.
- Strong Financial Performance: The company has consistently delivered solid financial results, which provides stability and resources for future growth.
Weaknesses
- Dependence on a Limited Product Range: Despite having a diverse portfolio, United Therapeutics Corp relies heavily on a few key products for the majority of its revenue.
- High Production Costs: The manufacturing process of certain medications can be expensive, resulting in lower profit margins for the company.
- Vulnerability to Regulatory Changes: Strict regulations and evolving compliance requirements in the pharmaceutical industry may pose challenges for United Therapeutics Corp.
- Limited Global Market Reach: The company's operations are primarily focused in specific regions, potentially hindering growth opportunities in untapped markets.
Opportunities
- Growing Demand for Innovative Therapies: With the increasing prevalence of various medical conditions, there is a significant market demand for new and improved treatment options.
- Expansion into International Markets: United Therapeutics Corp can explore new markets globally to extend its reach and tap into potential revenue streams.
- Strategic Partnerships and Collaborations: Forming alliances with other pharmaceutical companies or research institutions can enhance research capabilities and facilitate product development.
- Technological Advancements: Incorporating cutting-edge technologies into its product offerings can help United Therapeutics Corp stay competitive and meet evolving patient needs.
Threats
- Intense Competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share, which may impact United Therapeutics Corp's growth prospects.
- Patent Expirations: The expiration of patents for certain medications may lead to increased competition from generic drug manufacturers, potentially reducing the company's market share.
- Regulatory and Legal Challenges: United Therapeutics Corp must navigate complex regulations, potential legal disputes, and ongoing compliance requirements for its products.
- Economic Uncertainty: Economic fluctuations and changes in healthcare policies can affect customer purchasing power and reimbursement rates, impacting the company's revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.